Forest, Almirall to collaborate for new pulmonary disease therapy

By Elaine Rigoli

Tampa, Fla., April 10 - Forest Laboratories Holdings Ltd. and Almirall have agreed to develop, market and distribute Almirall's inhaled, long-acting muscarinic antagonist, LAS34273, in the United States.

Under terms of the agreement, Forest will make an upfront payment of $60 million to Almirall and will pay future undisclosed milestone payments, according to a news release.

In addition, Almirall will receive royalty payments based on LAS34273 sales.

Forest and Almirall will jointly oversee the development and regulatory approval of LAS34273 and share all expenses for current and future development programs, the release said.

LAS34273 is now entering phase 3 studies in the United States and Europe for chronic obstructive pulmonary disease and has been evaluated in phase 2 studies that demonstrate that it has a fast onset of action with a low level of systemic exposure.

According to the World Health Organization, chronic obstructive pulmonary disease is the fifth-leading cause of death worldwide and the fourth in the United States.

Forest Laboratories is a New York-based pharmaceutical company.

Almirall is a privately held pharmaceutical company headquartered in Barcelona, Spain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.